Helixgate https://validator.w3.org/feed/docs/rss2.html Samsung Biologics inks $262M manufacturing deal with European pharma company Encoded raises $275m for Dravet therapy and other financings UK review recommends ‘L plates’ for new healthcare AIs AbbVie charts a new course for CGRPs in menstrual migraine Hengrui gets world-first okay for platelet drug hetrombopag Synthetic biology Moderna flu vaccine wins FDA approval FDA approves oncolytic virus Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior Epidural Kit Correction: Medical Action Industries Issues Correction for Epidural Kits Containing Spectra Medical Devices Lidocaine Ampules Home Biotech’s 2026 IPOs deliver broad gains through August Novartis DM1 miss raises stakes for next wave of DMPK readouts Disc sets up polycythemia vera challenge but Silence maintains lead FDA places partial hold on Biohaven’s epilepsy drug mRNA cancer vaccines’ biggest barriers to market Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more STAT+: Cancer medicines remain in short supply across the U.S., survey finds Preclinical Pulse: The research catching our eye in September 2026 Rewriting the rules of genetic medicine with tRNA therapeutics TwoStep Therapeutics secures $62.5m funding to advance TS-104 Solstice Oncology secures $225m to drive porustobart’s development for cancer For PDUFA VIII, the most valuable incentive may be time August biopharma layoffs impact just over 500, down 90% year over year The supply chain fault lines of modern pharma Tyra shares slip as bladder cancer responses fall short of investor expectations Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’ Encoded raises $275M series F for Dravet syndrome gene therapy Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug Novartis’ board faces investor scrutiny after M&A misfires and R&D flops Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is coming StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in Patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke Precision Medicine Has a Commercialization Problem FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma Swiss CDMOS making moves: Lonza bets on new US facility, CordenPharma scales injectables with €80M AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters mRNA cancer vaccines’ biggest barriers to market Top 10 Contract Development and Manufacturing Organizations 2026 10 CDMO Up & Comers 2026 Revvity Signs Agreement to Acquire Human Cell Design Data Integrity as the Foundation for AI Smarter Cell Culture Starts with Better Media CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration